Company news
Soleno Therapeutics, Inc. news in 2024
Soleno Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
December 16, 2024
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
November 25, 2024
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024
November 13, 2024
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 5, 2024
Soleno Therapeutics to Participate in Upcoming November Investor Conferences
October 27, 2024
Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.
October 20, 2024
Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
October 7, 2024
Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference
September 15, 2024
Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
August 26, 2024
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2024
Soleno Therapeutics Announces Updates to its Board of Directors
August 14, 2024
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 6, 2024
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
June 27, 2024
Soleno Therapeutics Set to Join Russell 3000® Index
June 3, 2024
Soleno Therapeutics to Participate in Upcoming Investor Conferences
May 21, 2024
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
May 21, 2024
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
May 14, 2024
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 8, 2024
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
May 1, 2024
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
May 1, 2024
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome
April 29, 2024
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)
April 28, 2024
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 5, 2024
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
February 21, 2024
Soleno Therapeutics to Present at Upcoming February Investor Conferences
January 31, 2024
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
January 23, 2024